Clovis testing cancer drug on U.S. patient

BOULDER – Clovis Oncology Inc. has tested its first U.S. patient in its TIGER2 cancer study, the company announced this week.

Boulder-based Clovis (Nasdaq: CLVS)  is in the process of testing CO-1686, an oral targeted inhibitor of mutant forms of an epidermal growth-factor receptor for the treatment of non-small-cell lung cancer, according to the company. The testing is referred to as TIGER2.

“The CO-1686 data observed to date have been highly consistent, including the growing evidence of a lengthy duration of benefit and the tolerability profile of the drug,´ said Patrick J. Mahaffy, president and CEO of Clovis, in a statement.

The company plans on filing a new drug application by mid-2015, after several more months of testing.

Testing of CO-1686 first occurred in Japan in the first quarter.

You have 2 free articles remaining this month.
Want to see more? Login or Subscribe.
Molly Armbrister covers real estate, banking and health care for the Northern Colorado Business Report. She can be reached at 970-232-3139, or

Leave a Reply

Your email address will not be published. Required fields are marked *


Social Network

Facebook Icon
Twitter Icon
LinkedIn Icon
©2016 BizWest The contents of this website are copyright BizWest Media, LLC. All rights reserved.
Use of any of this informatino or media on this site is strictly prohibited withotu express written consent.